Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Cytokinetics (CYTK – Research Report) and keeping the price target at ...

The MAPLE-HCM trial, which is evaluating aficamten as monotherapy, is expected to complete enrollment in the third quarter of 2024, with results anticipated in the first half of 2025. This study ...

Cytokinetics (CYTK) provided guidance for corporate milestones expected to occur in 2025. Expected 2025 Milestones: Cardiac Muscle Programs: ...

Enrollment for the MAPLE-HCM trial, evaluating aficamten as monotherapy, is expected to be completed in the third quarter of 2024, with results anticipated in the first half of 2025. Additional ...

Cytokinetics, Inc. announced that Sanofi will acquire exclusive rights to aficamten from Corxel Pharmaceuticals ... regulatory approvals for trial commencement, progression or product sale or ...

Aficamten is also currently being evaluated in MAPLE-HCM, a Phase 3 clinical trial of aficamten as monotherapy compared to metoprolol as monotherapy in patients with obstructive HCM, ACACIA-HCM ...

Aficamten is also being evaluated in additional ... our ability to timely report the results of the MAPLE-HCM trial, and our ability achieve any element of our Vision 2030. Such statements are ...

The MAPLE-HCM trial, which is evaluating aficamten as monotherapy, is expected to complete enrollment in the third quarter of 2024, with results anticipated in the first half of 2025. This study could ...

Dec. 20, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Sanofi will acquire exclusive rights to develop and commercialize aficamten from Corxel ...

Dec. 20, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Sanofi will acquire exclusive rights to develop and commercialize aficamten from Corxel ...